It looks like they are acknowledging all their screw ups in this quarter.
They are taking the $21 mil Amphastar charge, deep sixing Humira at a cost of $42 million to pay GSK for unused manufacturing and they are in the process of reducing their lease situation.
Copaxone rev came in at $3 mil. Wow
Flo, all I can say is the management who just wasted $112 mil promises tomorrow will be better. They'll still bonus out not matter what happens to the stock holders. Can we believe them?
Market Data 
Markets 
AI
